SCHEMBL4779980

SCHEMBL4779980

NC(Cc1ccccc1C(F)(F)F)C(=O)N1CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
KDM4E B2RXH2 2/20 0.62
DPP4 P27487 6/20 0.53
FAP Q12884 2/20 0.53
DPP8 Q6V1X1 2/20 0.53
DPP9 Q86TI2 2/20 0.53
HSD11B1 P28845 1/20 0.50
LMNA P02545 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
DPP7 Q9UHL4 1/20 0.48
MAPT P10636 1/20 0.47
ALOX15 P16050 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP3A4 P08684 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
TSHR P16473 1/20 0.45
SLC6A7 Q99884 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773494 0.84 DPP4 (0.55) ALDH1A1MEN1KMT2AKDM4EDPP4
SCHEMBL4775817 0.84 CACNA2D1 (0.54) MEN1KMT2ADPP4FAPDPP8
SCHEMBL4778529 0.83 HDAC8 (0.54) ALDH1A1MEN1KMT2AKDM4EDPP4
SCHEMBL4776766 0.83 L3MBTL1 (0.53) ALDH1A1MEN1KMT2AKDM4EDPP4
SCHEMBL4773213 0.82 HDAC8 (0.51) ALDH1A1MEN1KMT2AKDM4EDPP4
SCHEMBL4770799 0.82 HDAC8 (0.63) ALDH1A1MEN1KMT2AKDM4EDPP4
SCHEMBL4775342 0.81 AKT1 (0.57) ALDH1A1KDM4EDPP4LMNACYP3A4
SCHEMBL4770733 0.81 L3MBTL1 (0.54) ALDH1A1KDM4EDPP4FAPDPP8
SCHEMBL28864313 0.79 ALDH1A1 (0.95) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL4779245 0.78 SIGMAR1 (0.55) MEN1KMT2ADPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 ALDH1A1 1068/4885MEN1 1807/4885KMT2A 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.